Omeros Corporation Releases Fourth Quarter and Full-Year 2025 Financial Results
Omeros Corporation has reported a transformative set of financial and operational results for the fourth quarter and full year ended December 31, 2025, marking a pivotal period in the company’s evolution from a development-stage organization to a commercially active biopharmaceutical player. The year was characterized by a combination of strategic transactions, regulatory achievements, pipeline progress, and significant improvements in financial performance, positioning the company for continued growth in the years ahead.
Strong Financial Turnaround Driven by Strategic Transactions
Omeros reported net income of $86.5 million, or $1.22 per share, for the fourth quarter of 2025, a dramatic turnaround from a net loss of $31.4 million, or $0.54 per share, in the same period of 2024. On a full-year basis, the company posted a near break-even performance, with a net loss of just $3.4 million, or $0.05 per share, compared to a substantial net loss of $156.8 million, or $2.70 per share, in the prior year.
This marked improvement was largely driven by a major strategic transaction involving Novo Nordisk, which significantly bolstered Omeros’ financial position. The fourth quarter included a net gain of $237.6 million related to the sale and licensing of zaltenibart (formerly OMS906), a key pipeline asset targeting MASP-3. This transaction provided immediate liquidity and long-term financial upside through milestone payments and royalties.
However, the reported results also included a $136.0 million non-cash charge tied to mark-to-market adjustments on embedded derivatives associated with the company’s 2029 Notes and term loan. When excluding these non-cash impacts, Omeros reported non-GAAP adjusted net income of $222.5 million, or $3.14 per share, for the fourth quarter, and $133.4 million, or $2.10 per share, for the full year—highlighting the strength of its underlying business performance.
Transformational Zaltenibart Deal with Novo Nordisk
A major highlight of the year was the closing of the Asset Purchase and License Agreement (APLA) with Novo Nordisk on November 25, 2025. Under this agreement, Novo Nordisk obtained exclusive global rights to develop and commercialize zaltenibart across all indications, along with related antibodies and products.
Zaltenibart is a human monoclonal antibody targeting MASP-3, a key component of the complement system involved in immune and inflammatory processes. The deal underscores the growing interest in complement pathway therapeutics as a promising area for treating rare and immune-mediated diseases.
In exchange, Omeros received an upfront cash payment of $240 million. In addition, the company is eligible for substantial future payments, including up to $510 million in development and regulatory milestones, up to $1.3 billion in commercial milestone payments, and tiered royalties on global net sales ranging from high single-digit to high-teen percentages.
Importantly, Omeros retained rights to its MASP-3 small-molecule program, as well as certain “grandfathered” antibody assets, allowing it to continue developing complementary therapies within this pathway.
Strengthened Balance Sheet and Debt Reduction
The influx of capital from the Novo Nordisk transaction enabled Omeros to significantly strengthen its balance sheet. The company used a portion of the proceeds to fully repay its $67.1 million senior secured term loan, including associated fees and interest, resulting in the termination of the credit agreement and the release of all related liens and covenants.
Additionally, Omeros repaid the remaining $17.1 million in principal on its 2026 convertible notes at maturity in February 2026. As a result, total debt was reduced to $87.9 million as of December 31, 2025, representing a decrease of $77.1 million, or nearly 47%, compared to the previous year.
The company ended 2025 with $171.8 million in cash and short-term investments, providing a solid financial foundation to support ongoing operations, product commercialization, and pipeline development.
FDA Approval and Launch of YARTEMLEA
Another major milestone for Omeros was the approval by the U.S. Food and Drug Administration (FDA) of YARTEMLEA® (narsoplimab-wuug) on December 23, 2025. The therapy was approved for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a rare but often fatal complication of stem cell transplantation.
YARTEMLEA is the first and only approved therapy for TA-TMA, representing a significant breakthrough for patients with this life-threatening condition. The drug works by selectively inhibiting MASP-2, a key enzyme in the lectin pathway of the complement system, thereby preventing pathway activation while preserving other immune functions critical for host defense.
Commercial launch activities began in January 2026, with both adult and pediatric patients already receiving treatment in hospital and outpatient settings. Notably, the therapy is being used in patients who have failed prior off-label treatments, including C5 and C3 inhibitors.
Omeros has deployed a dedicated commercial team across the United States, including account managers, medical science liaisons, and market access specialists, to support adoption and engagement with transplant centers nationwide.
European Regulatory Progress
Beyond the U.S., Omeros is pursuing international expansion for YARTEMLEA. A Marketing Authorization Application (MAA) is currently under review by the European Medicines Agency, with a decision anticipated in mid-2026. Approval would enable commercialization across European Union member states and European Economic Area countries, significantly expanding the drug’s market reach.
Pipeline Advancements Across Multiple Therapeutic Areas
Omeros continues to advance a diverse and innovative pipeline across multiple therapeutic areas, including addiction, oncology, and infectious diseases.
One notable program is its phosphodiesterase 7 (PDE7) inhibitor, OMS527, being developed for cocaine use disorder. The company previously received a $6.24 million grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to support preclinical and clinical studies.
Preclinical studies have been completed and demonstrated no safety concerns or drug interactions with cocaine, supporting progression to human trials. However, the FDA has requested additional preclinical data before initiating inpatient clinical studies. Omeros plans to meet with the agency alongside NIDA collaborators to address these requirements.
In oncology, the company is advancing its OncotoX-AML program, targeting acute myeloid leukemia (AML), an aggressive and often fatal blood cancer. The lead candidate has shown promising efficacy across multiple genetic subtypes, including TP53, NPM1, KMT2A, and FLT3 mutations, which collectively account for the majority of AML cases.
Preclinical studies, including nonhuman primate models, have demonstrated strong pharmacologic activity, including up to 99% reduction in myeloid progenitor cells. The therapy was well tolerated, with no significant safety concerns observed. IND-enabling studies are currently underway.
Omeros is also advancing its Targeted Complement Activating Therapy (T-CAT) platform, a novel class of recombinant antibodies designed to directly kill pathogens, including bacteria, fungi, viruses, and parasites. Initial efforts are focused on multidrug-resistant organisms (MDROs), a growing global health threat. Preclinical studies have demonstrated efficacy against both Gram-positive and Gram-negative bacteria, including pathogens identified by the World Health Organization as high priority.
Operational Efficiency and Expense Management
Total operating expenses for 2025 were $122.8 million, down from $167.0 million in 2024, reflecting a reduction of $44.2 million. This decrease was primarily due to lower manufacturing activity and the completion of certain clinical programs in the prior year. The company also implemented cost-control measures to conserve capital ahead of the YARTEMLEA launch.
Interest expense declined by $25.6 million year-over-year, largely due to changes in non-cash remeasurement costs associated with royalty obligations. Meanwhile, interest and other income decreased to $4.1 million, reflecting lower average cash balances during the year.
Royalty and Discontinued Operations Performance
Omeros continues to receive royalties from OMIDRIA, a product commercialized by Rayner Surgical. In the fourth quarter of 2025, royalties totaled $9.2 million on U.S. net sales of $30.7 million, slightly lower than the prior year. However, under agreements with DRI Health Acquisition, these royalties are currently being remitted to DRI through an escrow arrangement.
Net income from discontinued operations was $1.5 million in 2025, compared to $25.8 million in 2024, with the decline primarily driven by non-cash adjustments.
Leadership Perspective and Future Outlook
Commenting on the company’s performance, Chairman and CEO Gregory A. Demopulos highlighted the significance of 2025 as a transformative year for Omeros. He emphasized the successful FDA approval and launch of YARTEMLEA, the strategic partnership with Novo Nordisk, and the strengthening of the company’s financial position.
Looking ahead, Omeros aims to leverage these achievements to build a diversified portfolio of commercial products while advancing its pipeline. The company is targeting positive cash flow by 2027, supported by anticipated milestone payments, royalties, and product revenues.
Overall, Omeros Corporation’s 2025 results reflect a company undergoing a major transition, marked by scientific validation, regulatory success, and financial strengthening. With a newly approved product, a high-value partnership, and a robust pipeline, Omeros is well-positioned to enter its next phase of growth as a commercial-stage biopharmaceutical company focused on addressing critical unmet medical needs.
About Omeros Corporation
Omeros is an innovative biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for both large-market and orphan indications, with a focus on complement-mediated diseases, cancers, and addictive or compulsive disorders. Omeros’ lead complement inhibitor YARTEMLEA® (narsoplimab-wuug), which targets the lectin pathway’s effector enzyme MASP-2, is FDA-approved and commercially available in the U.S. for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adult and pediatric patients aged two years and older. A marketing authorization application seeking approval of YARTEMLEA for TA-TMA is currently under review at the European Medicines Agency. OMS1029, Omeros’ long-acting MASP-2 inhibitor, has successfully completed Phase 1 clinical trials.
Under a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), an inhibitor of MASP-3, the alternative pathway’s key activator, which is in clinical development for PNH and other alternative pathway indications, along with associated intellectual property and related assets. Omeros’ pipeline also includes OMS527, a phosphodiesterase 7 inhibitor in clinical development for cocaine use disorder, which is fully funded by the National Institute on Drug Abuse, and a growing portfolio of novel recombinant antibodies targeting multidrug-resistant organisms and novel molecular and cellular therapeutic programs for oncology.
Source Link:https://www.businesswire.com/
